Asundexian and Infarct Patterns on Brain MRI in PACIFIC-Stroke
The recurrence rate of ischemic stroke remains substantial despite advances in secondary prevention, reaching 5 to 8% at three months in recent clinical trials. 1-4 Combining antiplatelet treatment with anticoagulant therapy (i.e., dual pathway inhibition) is a promising secondary prevention strategy to address residual thrombotic risk, 5 showing benefit in stable cardiovascular disease 6 and peripheral artery disease after revascularization. 7 Asundexian is an oral direct inhibitor of FXIa with a